rs1245101 (NCAM1): Neurociticism association
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- The rs1245101 variant is linked to neurociticism with a strong effect size and low p-value.
- NCAM1 expression drops in the adrenal gland but rises in muscle and skin.
- No lifestyle considerations are reported for this variant.
Key takeaways
- The rs1245101 variant is linked to neurociticism with a strong effect size and low p-value.
- NCAM1 expression drops in the adrenal gland but rises in muscle and skin.
- No lifestyle considerations are reported for this variant.
What the research says The rs1245101 variant is associated with neurociticism, reported effect size 5.86 p=5e-9 in about 380 thousand individuals [PMID 29500382].
Reported associations Neurociticism: the variant is associated with increased risk, reported effect size 5.86 p=5e-9 in about 380 thousand individuals [PMID 29500382].
Evidence quality The supplied studies do not report a direct trait association for this variant; the rsid appears via GWAS Catalog [PMID 29500382]. The evidence is strong with large sample size and low p-value.
Tissue- specific expression effects
- NCAM1: reduced expression in adrenal gland GTEx Portal
- NCAM1: increased expression in muscle skeletal and skin not sun exposed suprapubic GTEx Portal
- NCAM1-AS1: increased expression in muscle skeletal GTEx Portal
No lifestyle considerations on file for this variant.
Frequently asked questions
What does rs1245101 mean?
It is a single nucleotide change in NCAM1 that has been associated with neurociticism.
Is the effect size large?
Yes, the GWAS reports an effect size of 5.86 and p=5e-9.
Can this affect my health?
The study does not link the variant to a specific disease; it only shows association with neurociticism.